(Sharecast News) - Brain health specialist Cambridge Cognition announced a strategic partnership with ActiGraph, a provider of wearable technologies tailored for clinical trials, on Wednesday.
The AIM-traded firm said the collaboration was intended to yield a comprehensive suite of assessments, offering a holistic perspective on both mental and physical capabilities.
At the core of the partnership was ActiGraph's 'Accelerant' partnership programme, which was intended to propel the use of digital health technologies (DHTs) within clinical development by streamlining access to raw data streams for clinical research organisations (CROs) and technology vendors.
In the context of the new alliance, Cambridge Cognition said it and ActiGraph would use their expertise in digital data collection to augment assessment capabilities within central nervous system (CNS) trials, particularly in domains marked by significant unmet needs such as schizophrenia and dementia.
Cambridge Cognition said it would bring its suite of touch-screen and voice-based digital assessments to the table, known for their precision and sensitivity in gauging cognition and other indicators of brain health.
"CNS disorders are characterised by a host of heterogeneous symptoms which impact daily life, but that are often inadequately addressed by existing treatments," said Cambridge Cognition's chief scientist Francesca Cormack.
"Our partnership with ActiGraph represents an exciting combination of expertise in objective digital measures of actigraphy, speech and cognition that will help accelerate the development of treatments for patients and improve efficiency in clinical trials."
At 1156 GMT, shares in Cambridge Cognition Holdings were down 0.62% at 51.18p.
Reporting by Josh White for Sharecast.com.
Cambridge Cog (COG)